Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from Theralase Technologies ( (TSE:TLT) ).
Theralase Technologies’ interim clinical data for its light-activated Ruvidar (TLD-1433) bladder cancer therapy has been accepted for oral presentation at the 2026 European Association of Urology Congress in London. The data come from an international, multicenter Phase II study in BCG-unresponsive non-muscle invasive bladder cancer carcinoma in-situ, with patient enrollment now completed.
Interim results indicate a promising safety and efficacy profile, including complete responses in two-thirds of treated patients and durable responses in some patients lasting 15 months to over three years after a single treatment. Theralase plans to begin rolling submissions of the clinical data to Health Canada and the U.S. FDA in the third quarter of 2026 and, pending anticipated 2027 approvals, aims to commercialize the technology initially in Canada and the United States, potentially reshaping treatment options for high-risk bladder cancer patients facing radical cystectomy.
The most recent analyst rating on (TSE:TLT) stock is a Hold with a C$0.25 price target. To see the full list of analyst forecasts on Theralase Technologies stock, see the TSE:TLT Stock Forecast page.
Spark’s Take on TSE:TLT Stock
According to Spark, TipRanks’ AI Analyst, TSE:TLT is a Neutral.
The score is held down primarily by weak financial performance—very large losses versus a small and declining revenue base, ongoing cash burn, and substantial equity erosion. Technicals provide some support with strong recent momentum (price above major moving averages and positive MACD), but elevated RSI suggests the move may be stretched. Valuation remains unattractive due to negative earnings and no dividend yield.
To see Spark’s full report on TSE:TLT stock, click here.
More about Theralase Technologies
Theralase Technologies Inc. is a clinical-stage pharmaceutical company focused on developing energy-activated small molecules to safely and effectively destroy cancer, bacteria and viruses. The company’s lead bladder cancer therapy, light-activated Ruvidar (TLD-1433), targets Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer, positioning Theralase in a niche for patients who have exhausted standard care options.
Average Trading Volume: 229,935
Technical Sentiment Signal: Strong Buy
Current Market Cap: C$69.41M
Find detailed analytics on TLT stock on TipRanks’ Stock Analysis page.